Pulse Biosciences (FRA:6L8) ROCE % : -88.13% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Pulse Biosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pulse Biosciences's annualized ROCE % for the quarter that ended in Mar. 2024 was -88.13%.

Pulse Biosciences ROCE % Historical Data

The historical data trend for Pulse Biosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulse Biosciences ROCE % Chart

Pulse Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-92.74

-133.74

-163.59

-101.17

-68.91

Pulse Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-56.29	-61.46	-69.98	-87.74	-88.13

Pulse Biosciences ROCE % Calculation

Pulse Biosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-39.957	/	( ( (73.516 - 5.646)	+	(54.244 - 6.151) )	/ 2 )
	=	-39.957	/	( (67.87	+	48.093)	/ 2 )
	=	-39.957	/	57.9815
	=	-68.91 %

Pulse Biosciences's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-39.064	/	( ( (54.244 - 6.151)	+	(45.231 - 4.675) )	/ 2 )
	=	-39.064	/	( ( 48.093	+	40.556 )	/ 2 )
	=	-39.064	/	44.3245
	=	-88.13 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Pulse Biosciences (FRA:6L8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pulse Biosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences (FRA:6L8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (FRA:6L8) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PLSE:USA

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Pulse Biosciences (FRA:6L8) Headlines

No Headlines